As COVID-19 cases resulting from infection with SARS-CoV-2 variants accumulate in the US and around the world, one question looms large:
How well do the COVID-19 vaccines developed so far protect against these novel coronavirus spinoffs?
“The virus is telling us it’s going to throw out a lot of mutations,” infectious disease specialist Jesse Goodman, MD, MPH, who, as then-chief scientist at the US Food and Drug Administration (FDA), led the agency’s response to the H1N1 influenza A pandemic, said in an interview. “Even if we don’t have a critical situation right at the moment…there’s a realistic possibility that variants will continue to evolve that have potential to avoid vaccine immunity.”